Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

July 28, 2019

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions
Facial AngiofibromaTuberous Sclerosis
Interventions
DRUG

rapamycin

Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks

DRUG

placebo

Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks

Trial Locations (17)

4101

Children's Health Queensland, Brisbane

8011

Canterbury District Health Board, Christchurch

11000

Clinic of Neurology and Psychiatry for Children and Youth, Belgrade

Clinical Center of Serbia, Belgrade

22903

University of Virginia, Charlottesville

28007

Clínica Universidad de Navarra, Madrid

31008

Clinica Universidad de Navarra, Pamplona

33701

All Children's Research Institute, St. Petersburg

49503

Spectrum Health, Grand Rapids

55905

Mayo Clinic, Rochester

83340

Narodný ústav detských chorȏb, Bratislava

85016

Phoenix Children's Hospital, Phoenix

92037

University of California San Diego, La Jolla

5HG9+4W

Fakultni nemocnice Brno, Brno

G39Q+49

Bethesda Children's Hospital of the Hungarian Reformed Church, Budapest

H-7624

University of Pécs, Pécs

Unknown

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

Dermatology Specialties Limited Partnership

INDUSTRY

NCT03826628 - Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex | Biotech Hunter | Biotech Hunter